i’ve built a diversified yet somewhat concentrated portfolio with a mix of broad market ETFs (VTI, VTV, VXUS), small-cap/value tilts (AVUV, AVDV, IWO), targeted growth plays in (AMD, SMH, Microsoft, XBI) and cash management in (JPST) My goal is long-term appreciation with some tactical bets.
Should I swap XBI for XLV for more stability, or keep the higher-risk biotech exposure?
IWO vs. AVUV Both give small-cap exposure, but AVUV leans value while IWO is pure growth. Should I consolidate?
Thoughts?